Lessons learned in migrating from one commercial genetics clinical decision-making tool to another: Assessment of data integrity and utilization
There was high data integrity after migration from one commercial software solution to another. Although these results can ease clinicians' concerns after such support tool transitions, our effort also highlights areas for improvement in how family and patient genetic data are recorded and utilized for clinical care and research within an institution.
Authors
- Mercy Laurino (ORCID: https://orcid.org/0000-0001-7152-5048)
- weibiao liu (ORCID: https://orcid.org/0009-0008-4572-6645)
- Nicole-Ann Rodis
- Marianne Dubard-Gault (ORCID: https://orcid.org/0000-0002-5735-1819)
- Haiquan Lu (ORCID: https://orcid.org/0000-0001-6570-7208)
- Kevin Tatunay
- Calvin Le
- Tae-Woo Nam
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Swedish Medical Center (US)
- Swedish Medical Center (US)
- Laguna Research (US)
- Ambry Genetics (United States) (US)
Publication Details
- Journal
- Genetics in Medicine Open
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.gimo.2024.101913
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Strong